VA-REGULA
When it comes to verifying identity in remote scenarios, it’s generally through liveness checks that organizations try to ensure they are dealing with a real individual. Fraudsters are perfectly aware of this fact, and therefore seek to bypass verification using various tactics, predominantly presentation or injection attacks. The first type of fraud involves attempts to trick the system by presenting fake biometric traits, such as photos, videos, masks, etc. Injection attacks are done by inserting altered biometric data directly into the process of identity verification (IDV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403567119/en/
A presentation attack scenario blocked by Regula Face SDK (Photo: Business Wire)
To help organizations secure remote IDV processes, Regula offers powerful technologies capable of detecting even the most sophisticated biometric fraud, including presentation and injection attacks. This latest update marks an advancement in Regula’s ability to detect certain types of spoofing attacks.
Enhanced security. Now, Regula Face SDK, a comprehensive solution for biometric verification, has reached a 99% rate in detecting and blocking presentation attacks done from electronic devices. Its anti-spoofing technology ensures that the face detected during the verification process is from an actively present and real person.
Streamlined user experience. Also, the new release of Regula Face SDK brings a new level of usability to biometric verification, thanks to the introduction of Passive Liveness technology. Utilizing neural networks trained on a diverse dataset, this technology verifies the genuine presence of an individual without any active participation from users (unlike Active Liveness) – the solution just requires them to take a selfie.
To obtain proper data for verification, i.e., a high-quality face image, Regula Face SDK uses an advanced image capture module that assesses image quality in real time, reducing the need for retakes. Followed by an instant liveness check, this approach significantly streamlines the overall verification process, making it faster and more user-friendly while maintaining high security standards.
“Remote onboarding is our new reality. More risky for organizations and definitely more preferable for users, it is about finding the perfect balance between security and convenience. The Passive Liveness feature is a delicate solution to this equation. It’s a very accessible single step for the user, improving user experience and elevating conversion rates. But that’s not all: Passive Authentication still ensures a high level of trustworthiness in the IDV process, as it effectively proves the presence and realness of an individual. Plus, for those who need ultimate security during onboarding or user verification, there is still the option of choosing Active Liveness, a more user-involving and robust technology for proving liveness,” says Ihar Kliashchou, Chief Technology Officer at Regula.
For the sake of greater convenience and faster interaction, the updated Regula Face SDK also supports face matching on mobile devices, without transmitting data to a server. Now, even if a smartphone is offline, it is still possible to compare a photo from a document with a selfie when identity verification is done not remotely, but on-site by an employee, for example in a bank when a client wants to open an account or get access to other financial services.
To learn more about the capabilities of the new version of Regula Face SDK, visit the official webpage.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403567119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom